vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and Marwynn Holdings, Inc. (MWYN). Click either name above to swap in a different company.

Marwynn Holdings, Inc. is the larger business by last-quarter revenue ($2.3M vs $1.8M, roughly 1.3× INVO Fertility, Inc.). Marwynn Holdings, Inc. runs the higher net margin — -116.0% vs -150.5%, a 34.5% gap on every dollar of revenue. On growth, INVO Fertility, Inc. posted the faster year-over-year revenue change (22.6% vs -13.3%).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

Marwynn Holdings, Inc. is a Canada-based investment holding company focused on acquiring, managing, and scaling middle-market businesses primarily across North America. Its core operating segments cover industrial products, consumer goods, and technology-enabled services, targeting sustainable long-term value creation for its stakeholders.

IVF vs MWYN — Head-to-Head

Bigger by revenue
MWYN
MWYN
1.3× larger
MWYN
$2.3M
$1.8M
IVF
Growing faster (revenue YoY)
IVF
IVF
+35.9% gap
IVF
22.6%
-13.3%
MWYN
Higher net margin
MWYN
MWYN
34.5% more per $
MWYN
-116.0%
-150.5%
IVF

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
IVF
IVF
MWYN
MWYN
Revenue
$1.8M
$2.3M
Net Profit
$-2.6M
$-2.7M
Gross Margin
42.4%
Operating Margin
-93.1%
-115.8%
Net Margin
-150.5%
-116.0%
Revenue YoY
22.6%
-13.3%
Net Profit YoY
-62.2%
-11713.9%
EPS (diluted)
$-0.77
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
MWYN
MWYN
Q3 25
$1.8M
$2.3M
Q2 25
$1.9M
Q1 25
$1.6M
$623.7K
Q4 24
$1.7M
Q3 24
$1.4M
Q2 24
$1.8M
Q1 24
$1.6M
Q4 23
$1.4M
Net Profit
IVF
IVF
MWYN
MWYN
Q3 25
$-2.6M
$-2.7M
Q2 25
$-5.3M
Q1 25
$-17.4M
$23.4K
Q4 24
$-3.6M
Q3 24
$-1.6M
Q2 24
$-2.2M
Q1 24
$-1.6M
Q4 23
$-2.0M
Gross Margin
IVF
IVF
MWYN
MWYN
Q3 25
42.4%
Q2 25
Q1 25
35.2%
39.2%
Q4 24
41.4%
Q3 24
31.0%
Q2 24
53.1%
Q1 24
45.3%
Q4 23
33.0%
Operating Margin
IVF
IVF
MWYN
MWYN
Q3 25
-93.1%
-115.8%
Q2 25
-160.4%
Q1 25
-1042.1%
13.5%
Q4 24
-202.0%
Q3 24
-90.7%
Q2 24
-100.9%
Q1 24
-95.7%
Q4 23
-109.2%
Net Margin
IVF
IVF
MWYN
MWYN
Q3 25
-150.5%
-116.0%
Q2 25
-283.6%
Q1 25
-1060.1%
3.8%
Q4 24
-211.3%
Q3 24
-113.8%
Q2 24
-122.2%
Q1 24
-101.3%
Q4 23
-144.4%
EPS (diluted)
IVF
IVF
MWYN
MWYN
Q3 25
$-0.77
$-0.16
Q2 25
$-13.30
Q1 25
$-12.53
$0.00
Q4 24
$14.86
Q3 24
$-15.11
Q2 24
$-22.39
Q1 24
$-7.55
Q4 23
$-59.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
MWYN
MWYN
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
$2.3M
Total Assets
$18.8M
$11.6M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
MWYN
MWYN
Q3 25
Q2 25
Q1 25
$480
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
Total Debt
IVF
IVF
MWYN
MWYN
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
IVF
IVF
MWYN
MWYN
Q3 25
$5.8M
$2.3M
Q2 25
$2.6M
Q1 25
$3.3M
$2.4M
Q4 24
$12.7M
Q3 24
$-23.3K
Q2 24
$1.4M
Q1 24
$10.2K
Q4 23
$892.8K
Total Assets
IVF
IVF
MWYN
MWYN
Q3 25
$18.8M
$11.6M
Q2 25
$19.3M
Q1 25
$31.7M
$12.6M
Q4 24
$46.4M
Q3 24
$17.0M
Q2 24
$17.8M
Q1 24
$17.3M
Q4 23
$18.5M
Debt / Equity
IVF
IVF
MWYN
MWYN
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
MWYN
MWYN
Operating Cash FlowLast quarter
$-1.8M
$-95.1K
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-101.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
MWYN
MWYN
Q3 25
$-1.8M
$-95.1K
Q2 25
$-1.7M
Q1 25
$-3.5M
Q4 24
$-617.4K
Q3 24
$-640.8K
Q2 24
$-1.5M
Q1 24
$-260.6K
Q4 23
$-714.9K
Free Cash Flow
IVF
IVF
MWYN
MWYN
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.6M
Q4 24
$-696.3K
Q3 24
Q2 24
$-1.5M
Q1 24
$-310.3K
Q4 23
FCF Margin
IVF
IVF
MWYN
MWYN
Q3 25
-101.6%
Q2 25
-92.6%
Q1 25
-216.9%
Q4 24
-40.6%
Q3 24
Q2 24
-82.3%
Q1 24
-19.7%
Q4 23
Capex Intensity
IVF
IVF
MWYN
MWYN
Q3 25
0.5%
Q2 25
0.5%
Q1 25
0.9%
Q4 24
4.6%
Q3 24
0.0%
Q2 24
3.0%
Q1 24
3.2%
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IVF
IVF

Segment breakdown not available.

MWYN
MWYN

Other$1.3M57%
Revenue From Recyclable Ewaste Materials Sales$1.0M43%

Related Comparisons